Mebendazole Grindeks

Mebendazole, the active ingredient in Mebendazole Grindeks, is a benzimidazole anthelmintic presented as an oral tablet for oral use. It is employed to treat common intestinal worm infections in children and adults. GNH USA supplies Mebendazole Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebendazole is an anthelmintic drug that targets nematode parasites causing intestinal infections. - Ascariasis: eliminates Ascaris lumbricoides worms, reducing gastrointestinal symptoms. - Hookworm infection: eradicates Ancylostoma duodenale and Necator americanus, preventing anemia. - Trichuriasis (whipworm): clears Trichuris trichiura, improving bowel function. - Enterobiasis (pinworm): removes Enterobius vermicularis, relieving perianal itching.

Mebendazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Abdominal pain: mild to moderate discomfort. - Nausea: occasional feeling of queasiness. - Diarrhoea: loose stools during treatment. - Headache: transient mild headache. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Agranulocytosis: severe reduction in white blood cells. - Severe skin reactions: rash or Stevens‑Johnson syndrome. - Allergic reactions: swelling, breathing difficulty.

Before prescribing Mebendazole, consider the following safety measures. - Pregnancy: use only if clearly needed, as safety data are limited. - Breastfeeding: assess risk versus benefit, as drug may pass into milk. - Liver disease: monitor hepatic function in patients with pre‑existing liver conditions. - Blood disorders: exercise caution in individuals with a history of neutropenia or agranulocytosis. - Drug interactions: review concomitant medications for potential interactions. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mebendazole may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cimetidine: may increase mebendazole plasma levels, raising toxicity risk. - Antifungal azoles (e.g., ketoconazole): can elevate systemic exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug concentrations. - Warfarin: monitor INR as mebendazole may affect anticoagulation. - Antacids: may reduce absorption if taken simultaneously.